Inclusion Criteria:

• Patients must have newly diagnosed, limited stage SCLC (small cell lung cancer), with no prior radiotherapy. Patients are allowed to have had a resection or biopsy.
• Women of reproductive potential must have a negative serum pregnancy test at the study screening visit.
• Patients must give written informed consent to participate in the study.
• Patients must be able to take oral medication.
• Patients should be completely recovered from recent surgery.
• Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function.
• Patients must be evaluated by the radiation oncologist prior to study entry.

Exclusion Criteria:

• Extensive Stage SCLC.
• Women who are pregnant or lactating.
• Use of an investigational drug within 30 days prior to the first dose of study medication.
• Any medically/clinically significant active infection.
• Symptoms of the SCLC spreading to the brain.
• Patients with limited stage SCLC who have undergone complete resection with no measurable disease prior to starting chemotherapy.
• Severe medical problems, unrelated to SCLC, that would limit the patient's full ability to follow all study rules and procedures, or that would expose the patient to extreme risk.
• Other ongoing, immunotherapy or radiotherapy being administered at the time as study participation.